Warning: Creating default object from empty value in /home/altaywgm/public_html/wp-content/plugins/gaviasframework/redux/redux-framework/inc/class.redux_filesystem.php on line 29
New Reference: Enfortumab vedotin for previously treated advanced urothelial carcinoma - Altai Oncology
  1. Home /
    2. Altai Protocol Library /
  2. New Reference: Enfortumab vedotin for previously treated advanced urothelial carcinoma

Altai Protocol Library

1041 protocols and counting

All protocols with references and links

All protocols reviewed by a Medical Oncologist/Hematologist

All protocols in major guidelines included

Ability to create your own protocols

Kütüphanede Ara Ara
Altai Protocol Library

New Reference: Enfortumab vedotin for previously treated advanced urothelial carcinoma

New Reference: Enfortumab vedotin for previously treated advanced urothelial carcinoma
Study:
  • Randomized, open label phase III trial (EV-301)
  • Locally advanved/metastatic urothelial carcinoma, received platinum and progressed during/after PD-1/PD-L1 inhibitor
  • Enfortumab vedotin (n=301) vs. chemotherapy (DOCEtaxel, PACLitaxel, vinflunine; n=307)
Efficacy:
  • CR/ORR: 4.9%/40.6% vs. 2.7%/17.9%
  • Median PFS: 5.55 mos vs. 3.71 mos (HR: 0.62 [0.51-0.75])
  • Median OS: 12.88 mos vs. 8.97 mos (HR: 0.70 [0.56-0.89])
Safety:
  • Grade 3-4 AEs: Neutropenia (5% vs. 6%), febrile neutropenia (1% vs. 5%), neuropathy (3% vs. 2%), rash (7% vs. 0%)

N Engl J Med. Published online on Feb 12, 2021

Powles T, et al. Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma

https://doi.org/10.1056/NEJMoa2035807

Altai Chemo Planner

Quickly Prepare Accurate Chemotherapy Orders

Altai Chemo Planner employs Altai Protocol Library that includes over 1000 chemotherapy protocols for both Hematology and Oncology. You can find major guidelines' protocols, parenteral, and oral, in the library. Altai Protocol Library is frequently and regularly updated.

Learn More